Correction: Routine HIV Testing in Botswana: A Population-Based Study on Attitudes, Practices, and Human Rights Concerns
Sheri D. Weiser, Michele Heisler, Karen Leiter, Fiona Percy-de Korte, Sheila Tlou, Sonya DeMonner, Nthisiseng Phaladze, David R. Bangsberg, Vincent Iacopino

DOI: 10.1371/journal.pmed.0030261

In *PLoS Medicine*, volume 3, issue 7:

Table 3 should have listed Age (years) as Mean: 28.5, SD: 8.3 (not Mean: 8.3, SD: 9.6).

Minnehy Mukoma should have been included in the Acknowledgments for research design and implementation.

This correction note may be found online at DOI: 10.1371/journal.pmed.0030395.
Published October 31, 2006.
Citation: Correction: Routine HIV testing in Botswana: A population-based study on attitudes, practices, and human rights concerns. *PLoS Med* 3(10): e395. DOI: 10.1371/journal.pmed.0030395

Correction: Frequency of Adverse Events after Vaccination with Different Vaccinia Strains
Mirjam Kretzschmar, Jacco Wallinga, Peter Teunis, Shuqin Xing, Rafael Mikolajczyk

DOI: 10.1371/journal.pmed.0030272

In *PLoS Medicine*, volume 3, issue 8:

Under the section heading “Expected Death Toll during a Present-Day Mass Vaccination Campaign,” the numbers of expected deaths that were computed for a mass vaccination campaign were displayed as per million; they should be absolute numbers.

The corrected text should be: “Under those assumptions, in the Netherlands mass vaccination with NYCBH would lead to 9.8 deaths (95% CI [0, 30]), mass vaccination with Lister to 55.1 deaths (95% CI [7, 182]), and mass vaccination with Bern would lead to 303.5 deaths (95% CI [19, 1093]). In Germany mass vaccination with NYCBH would lead to 46.2 deaths (95% CI [6, 142]), mass vaccination with Lister would lead to 268.5 deaths (95% CI [39, 875]), and mass vaccination with Bern would lead to 1,381 deaths (95% CI [94, 4909]).”

This correction note may be found online at DOI: 10.1371/journal.pmed.0030429.
Published October 31, 2006.
Citation: Correction: Frequency of adverse events after vaccination with different vaccinia strains. *PLoS Med* 3(10): e429. DOI: 10.1371/journal.pmed.0030429

Correction: Regulating the Market in Human Research Participants
Trudo Lemmens, Paul B. Miller

DOI: 10.1371/journal.pmed.0030330

In *PLoS Medicine*, volume 3, issue 8:

Reference 13 was mistakenly not cited in the main article. It should have been added as a reference to the sentence: “Claims associated with costs of drug development merit careful scrutiny since they are often used as a rhetorical tool to argue for faster approval times or to justify the high price of pharmaceuticals [13].”

This correction note may be found online at DOI: 10.1371/journal.pmed.0030447.
Published October 31, 2006.
Citation: Correction: Regulating the market in human research participants. *PLoS Med* 3(10): e447. DOI: 10.1371/journal.pmed.0030447